Organoids increasingly used to model pancreatic cancer

Despite recent remarkable advances in the treatment of some cancers, pancreatic cancer patients still have one of the worst survival rates. Pancreatic ductal adenocarcinoma’s (PDAC) five-year survival is only 2%-9%. This poor prognosis can largely be attributed to two major factors. Firstly, owing to relatively benign presenting features, the disease is not diagnosed until it has progressed to advanced or metastatic stages in >70% of patients.